Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06931626 as recruiting, last updated 2026-07-24. Enrolment is 10 planned participants, an estimate. Interventions: NMS-03305293, Temozolomide. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/